ArticlePLOS digital health2026
MITO-VATION: Feasibility of a technology-supported structured home exercise program in Mitochondrial Disease.
Article in PLOS digital health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Exercise intolerance, combined with low levels of physical activity, are commonly observed in individuals with Primary Mitochondrial Disease (PMD). However, access to health professionals with expertise in prescribing exercise to this population is limited. The use of digital health technology (DHT) may be a feasible and acceptable approach for therapists to support people with PMD to increase levels of physical activity, including exercise. Ten participants with mild to moderate PMD were recruited. All were provided with an eight-week home exercise program via an online exercise prescription app and remotely monitored using a smart watch. Participants received telehealth supporting their home exercise regimen along with reminders to move from the smart watch. The primary outcomes were feasibility and acceptability. Secondary outcomes were physical performance measures and fatigue, measured pre- and post-intervention. Only 26% of eligible participants enrolled. There were no dropouts, and four minor adverse events reported. Most participants (80%) participated in 80% or more of the telehealth sessions and wore the smart watch on 80% or more days during the study. Daily step target achievement was poor and only one participant met their individualised target on ≥80% of days. Half the participants achieved their weekly target of 150 intensity minutes (heart rate >50% of their theoretical maximal heart rate) on 7 or more weeks. Home exercise program adherence was low with only 30% of participants completing 80% or more of the scheduled strength training sessions over 8 weeks. Post-hoc exploration found pre-intervention exercisers achieved 4 out of 5 intervention targets compared to 0 for non-exercisers. Acceptability outcomes extracted from post-program questionnaires were overall positive towards the smart watch and home exercise program. There were no meaningful changes in any physical outcome measures or fatigue post-test. The use of DHT may be feasible and acceptable for prescribing home exercise and monitoring activity levels in individuals with mild to moderate forms of PMD, particularly those with a history of exercise.
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.